Sphingolipids and hepatic steatosis.

Published

Journal Article (Review)

The development of a fatty liver predisposes individuals to an array of health problems including diabetes, cardiovascular disease and certain forms of cancer. Inhibition or genetic ablation of genes controlling sphingolipid synthesis in rodents resolves hepatic steatosis and in many cases wards off the health complications associated with excessive hepatic triglyceride accumulation. Examples include the pharmacological inhibition of serine palmitoyltransferase or glucosylceramide synthase or the genetic depletion of acid sphingomyelinase, which dramatically reduce hepatic triglyceride levels in mice susceptible to the development of a fatty liver. The magnitude of the effects on triglyceride depletion in these models is impressive, but the relevance to humans and the mechanism of action is unclear. Herein we probe into the connections between sphingolipids and triglyceride synthesis in an attempt to identify causal relationships and opportunities for therapeutic intervention.

Full Text

Cited Authors

  • Bikman, BT; Summers, SA

Published Date

  • January 2011

Published In

Volume / Issue

  • 721 /

Start / End Page

  • 87 - 97

PubMed ID

  • 21910084

Pubmed Central ID

  • 21910084

Electronic International Standard Serial Number (EISSN)

  • 2214-8019

International Standard Serial Number (ISSN)

  • 0065-2598

Digital Object Identifier (DOI)

  • 10.1007/978-1-4614-0650-1_6

Language

  • eng